Search Details

Word: pharma (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...million commercial birds?some 11%?be kept indoors or covered once the autumn wild-bird migration begins. But the policy won't be universally adopted, because some European countries lack adequate indoor space or the means to assure that all the chickens are staying safely cooped up. Swiss pharma firm Roche last week pledged to donate 3 million courses of the antiviral drug Tamiflu to the World Health Organization, in case the virus mutates into a form that can rapidly infect humans. But at least for now, authorities hope this virus is just for the birds...

Author: /time Magazine | Title: A Fatal Flight To Europe? | 8/29/2005 | See Source »

...medicine, "I found," she says, "that all roads were leading to the drug companies." This wasn't the conclusion of an innocent who'd blundered into the field. A former editor-in-chief of the New England Journal of Medicine, Angell understood better than most the methods of big pharma, but she still thought the industry was dedicated to finding new medicines. She's now sure she was wrong...

Author: /time Magazine | Title: Big Pharma Syndrome | 8/29/2005 | See Source »

David Brennan PHARMA TEAM TO THE PROS...

Author: /time Magazine | Title: People to Watch in International Business | 8/25/2005 | See Source »

...nothing else, analysts say, the verdict constitutes a stern rebuke to Big Pharma. Jurors heard plenty from the plaintiff's lawyers about Merck's aggressive sales and marketing tactics and about a corporate culture that, they claimed, prizes profits over honest science. Merck, however, is hardly alone in being accused of such things. Wyeth, for one, has set aside $21 billion to pay for claims stemming from fen-phen, its faulty diet-drug combo. Analysts estimate that Merck could be on the hook for more than $18 billion in Vioxx damages...

Author: /time Magazine | Title: Big Pharma's Bitter Pill | 8/22/2005 | See Source »

...introduced in the '80s - has helped make generics big business. Government encouragement of the sector means off-patent drugs account for more than half of the U.K. and U.S. markets by volume. Novartis CEO Daniel Vasella reckons the sector will be worth $100 billion by 2010. But other Big Pharma firms have sold out of the low-margin generics business in recent years - so is Novartis risking an overdose? In a sector where "the cost of production is really important," says Frances Cloud, senior pharmaceutical analyst at Nomura in London, at least "being big does help...

Author: /time Magazine | Title: Bizwatch | 2/28/2005 | See Source »

First | Previous | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | Next | Last